Suchergebnisse - "Shiu, Kai-Keen"

PubPharm (6)

1

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859) : a multicentre, randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Rha, S. | Oh, D. | Yañez, P. | +121

2

Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer

enthalten in: Cancer science | 2023

von Yoshino, T. | Andre, T. | Kim, T. | +17

3

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177) : final analysis of a randomised, open-label, phase 3 study

enthalten in: The Lancet. Oncology | 2022

von Diaz, L. | Shiu, K. | Kim, T. | +17

CommentIn: Lancet Oncol. 2022 Jun;23(6):e245. - PMID 35654062

4

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Adams, R. | Fisher, D. | Graham, J. | +19

CommentIn: J Clin Oncol. 2021 Nov 20;39(33):3656-3659. - PMID 34516761

5

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Andre, T. | Amonkar, M. | Norquist, J. | +17

6

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D) : a phase 2-3 randomised trial

enthalten in: The lancet. Gastroenterology & hepatology | 2018

von Adams, R. | Brown, E. | Brown, L. | +14

CommentIn: Lancet Gastroenterol Hepatol. 2018 Mar;3(3):143-145. - PMID 29254888

1
[1]